Carvedilol

Generic Name: Carvedilol

Brand Names: Coreg

Drug Type: Small Molecule

Chemical Formula: C_₂₄H_₂₆N_₂O_₄

CAS Number: 72956-09-3

Unique Ingredient Identifier: 0K47UL67F2

Background: Carvedilol is a racemic mixture where the S(-) enantiomer is both a beta and alpha-1 adrenoceptor blocker, and the R(+) enantiomer is an alpha-1 adrenoceptor blocker. It is currently used to treat heart failure, left ventricular dysfunction, and hypertension. The dual action of carvedilol is advantageous in combination therapies as moderate doses of 2 drugs have a decreased incidence of adverse effects compared to high dose monotherapy in the treatment of moderate hypertension.

Carvedilol was granted FDA approval on 14 September 1995.

Indication: Carvedilol is indicated to treat mild to severe heart failure, left ventricular dysfunction after myocardial infarction with ventricular ejection fraction ≤40%, or hypertension.

Associated Conditions: Atrial Fibrillation, Chronic Stable Angina Pectoris, Hypertension, LVEF ≤40% Left ventricular dysfunction, NYHA Class I or II heart failure, Chronic heart failure with reduced ejection fraction (NYHA Class III), Chronic heart failure with reduced ejection fraction (NYHA Class IV)

Associated Therapies: -

Clinical Trials

Pharmacological Reduction of Right Ventricular Enlargement

Phase 3

Recruiting

Conditions: Tricuspid Regurgitation
Right Ventricular Dilatation

Interventions: Drug: Carvedilol+Empagliflozin
Drug: Placebo
Drug: Carvedilol
Drug: Empagliflozin

First Posted Date: 2020-04-14

Last Posted Date: 2023-07-21

Lead Sponsor: Asan Medical Center

Target Recruit Count: 180

Registration Number: NCT04345796

Locations: 🇰🇷
Asan Medical Center, Seoul, Korea, Republic of
🇰🇷
Samsung Medical Center, Seoul, Korea, Republic of
🇰🇷
Seoul National University Hospital, Seoul, Korea, Republic of

HVPG-Guided Therapy vs Carvedilol Plus Endotherapy for the Prevention of Esophageal Variceal Rebleeding in Cirrhotic Patients

Not Applicable

Conditions: Esophageal Varices
Liver Cirrhoses
Variceal Hemorrhage

Interventions: Procedure: Transjugular intrahepatic portosystemic shunt
Procedure: Endoscopic variceal ligation
Drug: Carvedilol

First Posted Date: 2020-02-05

Last Posted Date: 2020-02-05

Lead Sponsor: Air Force Military Medical University, China

Target Recruit Count: 220

Registration Number: NCT04254822

Locations: 🇨🇳
Fourth Military Medical University, Xi'an, Shaanxi, China

Cardiac Changes in Early Parkinson's Disease: a Follow Up Study

Phase 2

Conditions: REM Sleep Behavior Disorder
Pre-motor Parkinson Disease
Symptomatic Parkinson Disease

Interventions: Drug: Carvedilol

First Posted Date: 2020-01-06

Last Posted Date: 2024-11-26

Lead Sponsor: Cedars-Sinai Medical Center

Target Recruit Count: 15

Registration Number: NCT04218968

Locations: 🇺🇸
Michele L Lima Gregorio, Los Angeles, California, United States

Autophagy Activation for the Alleviation of Cardiomyopathy Symptoms After Anthracycline Treatment, ATACAR Trial

Phase 2

Withdrawn

Conditions: Lymphoma
Hematopoietic and Lymphoid Cell Neoplasm
Breast Carcinoma
Sarcoma

Interventions: Drug: Carvedilol
Drug: Lisinopril
Drug: Pravastatin
Drug: Spironolactone

First Posted Date: 2019-12-09

Last Posted Date: 2023-05-24

Lead Sponsor: Mayo Clinic

Registration Number: NCT04190433

Mechanism of Masked Hypertension - Intervention

Phase 3

Withdrawn

Conditions: Masked Hypertension

Interventions: Drug: Carvedilol
Drug: Amlodipine

First Posted Date: 2019-10-09

Last Posted Date: 2021-11-05

Lead Sponsor: University of Alabama at Birmingham

Registration Number: NCT04121299

Locations: 🇺🇸
Hypertension Research Clinic at UAB, Birmingham, Alabama, United States

Risk-Guided Cardioprotection with Carvedilol in Breast Cancer Patients Treated with Doxorubicin And/or Trastuzumab

Phase 1

Active, not recruiting

Conditions: Toxicity Due to Chemotherapy
Cardiomyopathies
Heart Failure
Cardiotoxicity
Risk Factor, Cardiovascular
Breast Cancer

Interventions: Drug: Carvedilol

First Posted Date: 2019-07-17

Last Posted Date: 2024-10-16

Lead Sponsor: Abramson Cancer Center at Penn Medicine

Target Recruit Count: 69

Registration Number: NCT04023110

Locations: 🇺🇸
Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, United States

Anti-Cancer Effects of Carvedilol With Standard Treatment in Glioblastoma and Response of Peripheral Glioma Circulating Tumor Cells

Early Phase 1

Withdrawn

Conditions: Glioblastoma
Glioblastoma Multiforme

Interventions: Drug: Carvedilol

First Posted Date: 2019-06-10

Last Posted Date: 2021-04-12

Lead Sponsor: West Virginia University

Registration Number: NCT03980249

Locations: 🇺🇸
WVU Cancer Institute - Mary Babb Randolph Cancer Center, Morgantown, West Virginia, United States

Treating Breast Cancer Patients Undergoing Trastuzumab Treatment with Carvedilol to Reduce Incidence of Heart Failure

Phase 2

Recruiting

Conditions: Breast Cancer

Interventions: Drug: Carvedilol

First Posted Date: 2019-03-19

Last Posted Date: 2025-01-07

Lead Sponsor: Mayo Clinic

Target Recruit Count: 450

Registration Number: NCT03879629

Locations: 🇺🇸
Mayo Clinic, Phoenix, Arizona, United States
🇺🇸
Mayo Clinic in Florida, Jacksonville, Florida, United States
🇺🇸
Mayo Clinic in Rochester, Rochester, Minnesota, United States

and more 2 locations